简介
Lin Zhang has obtained the Medical Degree (MBBS) from Anhui Medical University, Master of Medicine(MMed) and Master of Public Health(MPH) from Peking Union Medical College/Tsinghua University, and Ph.D of Cancer Epidemiology from Melbourne School of Population and Global Health, the University of Melbourne. Lin was a Visiting Research Scientist in Monash University eResearch Centre and Erasmus University Medical Center. Lin’s research team was awarded the “2017 Award for Excellence” of the University of Melbourne. Because of excellent research outcome during in PhD, Lin was awarded the Victorian International Education Award by the Victorian State Government of Australia, and Global Outstanding Graduate by Ministry of Education of China in 2020.
With 12 years of experience in the clinical medicine, public health, pharmaceutical research, Lin worked as Attending Physician in Peking Union Medical College Hospital, Research Assistant in Victorian Comprehensive Cancer Centre/PeterMac Cancer Hospital and Teaching Assistant for Master of Public Health students in University of Melbourne, and Senior Medical Advisor in Sienna Cancer Diagnostics, Senior Research Scientist in Eli Lilly and Company. Currently, Lin is the General Manager and Chief Medical Officer of Ningbo Branch of Wondersgroup (SZSE:300168), a leading listed medical/healthcare data and health informatics company in China, and is responsible for the application of medical data in real-world evidence(RWE), R&D, and clinical research for pharmaceutical companies and CROs, responsible for connecting with the KOL. The main areas of work include pre-and post-marketing clinical research, medical big data research, post-marketing real-world research, pharmacoeconomics research, patient self-reported outcome research, and the application of artificial intelligence in the medical field, participating in post-marketing clinical strategies and implementation, to generate evidence to support clinical decision-making and market access.
Lin has 183 publications (H index=27) in medical and public health field, and 97 publications on international journals, including Lancet, BMJ, Lancet Haematol, Lancet Digital Health, Lancet Rheumatology, Nature Communication, Gastroenterology, Gut, Frontier in Oncology, etc. Published 2 co-authored books (including The Book of OHDSI：Observational Health Data Sciences and Informatics), and the co-author of 3 books of clinical practice. Lin is the member of the Global Burden of Disease (GBD) Collaborator Network and served as the Associate Editor of a special topic of Frontiers in Pharmacology, and compiled international publication related to PD-1/PD-L1 in cancer treatment. Lin also served as Corperate Supervisor in the Artificial Intelligence Research Group of Monash University, and a visiting professor at the University of Science and Technology of China.
